Postoperative Nausea and Vomiting Market
Report ID: SQMIG35H2595
Report ID: SQMIG35H2595
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35H2595 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
201
|Figures:
80
Global Postoperative Nausea And Vomiting Market size was valued at USD 2.3 Billion in 2024 and is poised to grow from USD 2.42 Billion in 2025 to USD 3.69 Billion by 2033, growing at a CAGR of 5.4% during the forecast period (2026-2033).
Postoperative nausea and vomiting is a large niche that continues to grow with increasing surgical volumes and changing anesthetic techniques. The market includes acute-phase PONV drugs/prophylactic devices/monitoring platforms following surgery. The importance of this market is tied to patient comfort, length of hospital stay, and total health care costs; studies suggest effective management of PONV can decrease postoperative admissions by as much as 15%. Until recently, the Postoperative nausea and vomiting market was primarily served with serotonin 5-HT3 receptor antagonists (such as ondansetron). However, with the arrival of NK-1 receptor antagonists and new non-opioid combinations in the 2010s, new treatment options have emerged; therefore, a shift has occurred from the sale of generics to patent-protected combination therapies due to the added complexity of the market.
Another driving force behind the Postoperative nausea and vomiting market is the increased volume of outpatient/minimally invasive surgery; this has increased the emphasis on rapid discharge (i.e., same-day protocols) and decreased side effects from medications, which has led facilities to use longer-acting NK-1 receptor antagonists and/or oral combination products to avoid delayed discharges due to the lack of adequately dosing patients before being discharged. This trend has encouraged pharmaceutical companies to support clinical trials demonstrating faster readiness for discharge from outpatient surgical settings, such as the 2022 study demonstrating a 30% reduction in time to recovery utilizing a triple combination therapy protocol. Consequently, insurers reimburse bundled peri‑operative packages that include PONV prophylaxis, creating revenue for manufacturers and spurring digital platforms that sync dosage timing with electronic records.
How is AI-driven Automation Influencing The Postoperative Nausea And Vomiting Market?
By incorporating artificial intelligence (AI) with predictive analytics into clinical workflows, AI-enabled automations are transforming the postoperative nausea/vomiting (PONV) market. Machine learning algorithms analyze patient demographic information, surgical procedure, and anesthesia record history to identify those who are at-risk for PONV prior to surgery. This allows for the selection of the most appropriate anti-emetic (nausea medication) therapy and adjustment of dosages in real time, minimizing trial/error prescribing of these medications. Automated infusion pumps, integrated with electronic health record systems (EHR), provide an accurate and precise amount of medication, while computerized natural language processing capabilities analyze postoperative notes and make recommended changes to the PONV guidelines. The end result is more rapid recovery, reduced complications, and improved efficiency across the supplies used to care for PONV patients, which further accelerates the growth of this sector.
In January 2026, UpToDate introduced a module for decision support using an AI-based method for developing personalized anti-emetic protocols based on real time patient data. The decision support module simplifies the physician order process, shortens medication preparation time, and improves accuracy of prophylactic treatment; demonstrating the positive impact that automation creates for hospitals' Postoperative nausea and vomiting marketplace and for individual patient experiences as well as overall patient safety.
Market snapshot - (2026-2033)
Global Market Size
USD 2.3 Billion
Largest Segment
Pharmacological Therapy
Fastest Growth
Non-Pharmacological Therapy
Growth Rate
5.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global postoperative nausea and vomiting market is segmented by treatment type, drug class, route of administration, application, end user, patient group, distribution channel and region. Based on treatment type, the market is segmented into Pharmacological Therapy and Non-Pharmacological Therapy. Based on drug class, the market is segmented into 5-HT3 Receptor Antagonists, NK1 Receptor Antagonists, Corticosteroids, Dopamine Antagonists, Antihistamines and Others. Based on route of administration, the market is segmented into Oral, Intravenous, Transdermal and Intramuscular. Based on application, the market is segmented into Prevention of Postoperative Nausea, Prevention of Postoperative Vomiting and Rescue Treatment of PONV. Based on end user, the market is segmented into Hospitals, Ambulatory Surgical Centers and Specialty Clinics. Based on patient group, the market is segmented into Adult, Pediatric and Geriatric. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The 5-HT3 Receptor Antagonists category is dominant as these agents act by blocking serotonin receptors involved in nausea pathway, thus providing rapid onset and dependable relief from nausea after surgical procedures. Clinicians prefer employing 5-HT3 Receptor Antagonists due to their established safety profile, ease of dosing as well as compatibility with a variety of anesthetic protocols. Use of 5-HT3 Receptor Antagonists across both adult patients and pediatric patients further highlights their central role in prophylactic regimens and supports maintenance of market leadership and physician confidence across a variety of surgical specialties.
As per postoperative nausea and vomiting market forecast, NK1 Receptor Antagonists will become the fastest growing segment as innovative formulations have enhanced bioavailability and have prolonged their effect during the delay period associated with post-operative nausea. Therefore, the growing usage of multimodal prophylaxis combined with a current increase in physician knowledge of NK1 Receptor Antagonist will establish NK1 Receptor Antagonist class as a key merchant of increased market development and new therapeutic opportunities.
The intravenous route is the primary source of antiemetic medication by providing rapid delivery of medication to achieve the rapid plasma concentrations necessary for successful nausea and vomiting results within minutes after the procedure is finished. Anesthesiologists utilize this method to synchronize the timing of antiemetic administration with the emergence of the patient from anesthesia, thus facilitating a seamless transition of the patient from the operating room to recovery. The ability to combine multiple agents into one infusion system improves the efficiency of the infusion process, reduces the potential for dosing errors, and integrates with the existing perioperative IV infrastructure; thus, this method is highly regarded by surgical teams.
As per postoperative nausea and vomiting market analysis, oral antiemetic medications are currently growing at a rapid pace due to the changing preferences of patients towards less invasive methods of receiving their medications after being discharged from the hospital. The introduction of long-acting tablets and dissolvable films creates opportunities for a greater convenience and better adherence to therapy, thus enhancing the ability to use these agents in ambulatory surgical centers. This growing trend supports the penetration of oral medications into the antiemetic market and will facilitate the development of cost-effective antiemetic alternatives for patients recovering from surgery at home.
To get detailed segments analysis, Request a Free Sample Report
The healthcare sector in North America is well advanced and has been around so long that it has established systems and networks for healthcare providers combining procedures (for example, actual surgery and administration of anesthetics) with perioperative care. Large volumes of hospitals (academic and community hospitals) practice evidence‑based medicine, with the integration of clinical research providing a significant number of effective products for preventing postoperative nausea/vomiting. At the same time, because of the strong evaporative phase of antiemetics, patients undergoing procedures have historically requested more comfort measures due to their experiences with the postoperative period. Therefore, the value of regulators to provide for faster approval of new drugs for the management of postoperative nausea/vomiting has played a critical role in substantiating North America's position as the leader in this marketplace.
The remaining limitations of the United States postoperative nausea and vomiting marketplace in number of outpatient and acute care centers receiving multimodal antiemetic therapy are primarily due to lack of training on incorporation of newer products with traditional antiemetics, the reimbursement rates associated with outpatient and short-stay hospitalization and their lack of availability from local suppliers/distributors. Additionally, many large academic institutions are continually working as research sites that will refine the dosing/scheduling of antiemetics for the clinical settings. As a result, many payers implement policies related to value based care that embed the use of antiemetic protocols within the procedures/imaging bundles, resulting in continued high demand for these products across different surgical specialties.
The Postoperative Nausea and Vomiting Market penetration in Canada operates within a publicly funded healthcare structure that emphasizes the adherence to clinical guidelines and cost effectiveness. Health authorities at the provincial level encourage the use of standardized antiemetic pathways, supporting uniformity through the hospitals in which they practice. Collaborative networks of clinicians and pharmacists support the rapid dissemination of best practice examples, with continued patient safety being of primary concern, lending itself to the ongoing evaluation of available therapeutic options. The introduction of new antiemetic agents into provincial formularies creates incremental market growth within a stable reimbursement environment.
The rapid growth of the European market has been fueled by a collaborative approach to regulatory harmonisation, along with an increased emphasis on patient-centered recovery from surgery. National healthcare systems are increasingly adopting comprehensive antiemetic guidelines that align with International standards, making the uptake of products more consistent. In addition, investment by the pharmaceutical industry into clinical research throughout Europe, has led to a greater understanding of the best use of different types of therapies in combination with one another. Collaborative activities between medical associations assist with knowledge transfer. Importantly, new entrants to the market will have the benefit of advantageous reimbursement measures which encourage innovation as well as the development of out-patient models to provide effective control of nausea and vomiting after surgery.
Postoperative Nausea and Vomiting Market in Germany is anchored by a strong tradition of evidence‑based practice and a dense network of specialized surgical centers. German clinicians emphasize precision dosing and early intervention, leading to high utilization of both established and novel anti‑emetic agents. The country’s robust health technology assessment framework ensures that new therapies gain swift acceptance when clinical benefits are demonstrated, reinforcing market depth. Continuous professional education sustains awareness of evolving guidelines, driving sustained market activity.
Postoperative Nausea and Vomiting Market in the United Kingdom reflects a dynamic environment where accelerated guideline updates and strong clinical research collaborations drive growth. NHS trusts prioritize integrated care pathways that embed prophylactic anti‑emetic regimens, encouraging consistent usage across elective procedures. Rapid adoption of innovative therapies is supported by streamlined procurement processes and a focus on enhancing patient experience. Educational initiatives targeting surgical teams promote best‑practice adoption, contributing to the market’s fast‑moving nature.
Postoperative Nausea and Vomiting Market in France is emerging as healthcare providers seek to align with European quality standards while addressing patient comfort. French hospitals increasingly adopt multimodal anti‑emetic protocols, integrating newer agents alongside conventional treatments. Collaborative research programs funded by national agencies stimulate evidence generation that supports guideline refinement. Reimbursement structures that reward improved postoperative outcomes encourage the inclusion of effective anti‑emetic options, fostering gradual market expansion.
Asia Pacific is strengthening its position through accelerated modernization of surgical facilities and heightened emphasis on peri‑operative patient well‑being. Regional healthcare systems are adopting international best practices while tailoring anti‑emetic protocols to local patient demographics. Investment in clinical trials and partnerships with global pharmaceutical firms bring innovative therapies to market, enhancing therapeutic options. Growing awareness of the economic impact of postoperative complications drives policymakers to support preventive anti‑emetic strategies, and the expansion of minimally invasive surgeries further elevates demand for effective nausea and vomiting control across the region.
Postoperative Nausea and Vomiting Market in Japan benefits from a culture of meticulous surgical care and a strong regulatory framework that facilitates timely approval of advanced anti‑emetic agents. Japanese hospitals integrate comprehensive anti‑emetic regimens into standard peri‑operative pathways, emphasizing early prophylaxis. Collaborative efforts between academic institutions and industry promote continuous refinement of therapeutic strategies, while national health insurance policies support broad access to effective treatments, sustaining market growth.
Postoperative Nausea and Vomiting Market in South Korea reflects rapid adoption of innovative anti‑emetic solutions within a technologically advanced healthcare system. Korean clinicians prioritize evidence‑based protocols that combine newer agents with established therapies, optimizing patient comfort. Government initiatives that encourage clinical research and streamline reimbursement for effective treatments bolster market confidence. The emphasis on shortened hospital stays and outpatient surgical procedures intensifies demand for reliable nausea and vomiting management, reinforcing the market’s expanding role.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Surgical Volumes Worldwide
Advancements In Antiemetic Drug Delivery
Stringent Regulatory Approval Processes
Limited Awareness Of PONV Impact
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape is shaped by firms leveraging strategic M&A, partnerships with anesthesia device manufacturers, and novel anti‑emetic delivery technologies; Heron Therapeutics has expanded its PONV Solutions portfolio through collaborations with surgical centers, while emerging players are securing seed capital to integrate digital monitoring into postoperative care, intensifying rivalry for market share and accelerating product pipelines.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global postoperative nausea and vomiting market is being propelled primarily by rising surgical volumes that expand the pool of patients needing anti‑emetic care, while a second engine of growth stems from innovative drug‑delivery technologies such as orally disintegrating tablets and long‑acting injectables that simplify peri‑operative protocols. The market is still constrained by stringent regulatory approval processes that lengthen development timelines and deter smaller innovators. North America remains the dominant region due to its mature healthcare infrastructure and strong reimbursement support. Within the product landscape, 5‑HT3 receptor antagonists continue to lead the segment share, reinforced by their proven safety and rapid onset.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.3 Billion |
| Market size value in 2033 | USD 3.69 Billion |
| Growth Rate | 5.4% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Postoperative Nausea and Vomiting Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Postoperative Nausea and Vomiting Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Postoperative Nausea and Vomiting Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Postoperative Nausea and Vomiting Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Postoperative Nausea And Vomiting Market size was valued at USD 2.3 Billion in 2024 and is poised to grow from USD 2.42 Billion in 2025 to USD 3.69 Billion by 2033, growing at a CAGR of 5.4% during the forecast period (2026-2033).
The competitive landscape is shaped by firms leveraging strategic M&A, partnerships with anesthesia device manufacturers, and novel anti‑emetic delivery technologies; Heron Therapeutics has expanded its PONV Solutions portfolio through collaborations with surgical centers, while emerging players are securing seed capital to integrate digital monitoring into postoperative care, intensifying rivalry for market share and accelerating product pipelines. 'Merck & Co., Inc.', 'Helsinn Group', 'Heron Therapeutics, Inc.', 'Eagle Pharmaceuticals, Inc.', 'Eisai Co., Ltd.', 'Baxter International Inc.', 'Pfizer Inc.', 'Sanofi S.A.', 'AstraZeneca PLC', 'Teva Pharmaceutical Industries Ltd.', 'Dr. Reddy's Laboratories Limited', 'Sun Pharmaceutical Industries Limited', 'Cipla Limited', 'Aurobindo Pharma Limited', 'Fresenius Kabi AG', 'Hikma Pharmaceuticals PLC', 'Amneal Pharmaceuticals, Inc.', 'Kyowa Kirin Co., Ltd.', 'Piramal Pharma Limited', 'Towa Pharmaceutical Co., Ltd.'
The surge in elective and emergency procedures across diverse healthcare systems is expanding the pool of patients at risk of postoperative nausea and vomiting, thereby driving demand for effective prophylactic and therapeutic agents. Greater awareness of patient comfort and the growing emphasis on enhanced recovery protocols encourage clinicians to adopt evidence‑based antiemetic regimens, which in turn stimulates market growth through increased product utilization and broader formulary inclusion. This broader therapeutic arsenal also facilitates compliance with clinical guidelines, encouraging consistent prescribing practices across institutions.
Precision Prophylaxis Integration: Healthcare providers are increasingly adopting individualized antiemetic protocols that align drug selection and dosing with patient-specific risk factors such as age, gender, surgical type, and genetic markers. This shift towards precision prophylaxis is driven by growing clinical evidence demonstrating reduced incidence of postoperative nausea and vomiting and shorter hospital stays. Pharmaceutical companies are responding by expanding their portfolios with agents designed for targeted use, while hospitals invest in decision‑support tools that embed risk‑assessment algorithms into peri‑operative workflows and improve outcomes.
Why does North America Dominate the Global Postoperative Nausea and Vomiting Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
